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Abstract
The endogenous neuropeptides nociceptin/orphanin FQ and nocistatin translated from the prepronociceptin gene 
exert a relaxant effect on the rat uterus. Previous studies have reported their role in pain transmission in the central 
nervous system both in rodents and in humans, but to date only limited information is available on their effects in the 
periphery, and there are no data on their presence in the human uterus.
The expression of prepronociceptin mRNA in the human uterus was confirmed by an RT-PCR technique. In vitro 
contractility studies of the action of nociceptin and nocistatin on human uterine tissues were performed in an isolated 
organ system. Human myometrial strips from cesarean sections at full-term pregnancy and at preterm labor were 
stimulated with oxytocin, and the relaxant effects of nociceptin and nocistatin were studied.
The level of prepronociceptin mRNA was significantly decreased in full-term pregnant uterus samples as compared 
with preterm pregnancy samples. Nociceptin and nocistatin significantly and dose-dependently inhibited the oxytocin-
evoked contractions in the human uterus. In the presence of nocistatin, the uterus-relaxant effect of nociceptin was 
enhanced. In contrast, nociceptin did not alter the uterus-relaxant effect of nocistatin.
We conclude that locally generated nociceptin and nocistatin both exert a relaxant effect on the human uterus, 
and nocistatin can potentiate the relaxant effect of nociceptin, though for this to occur nocistatin administration must 
precede the administration of nociceptin.
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Introduction
Preterm birth complicates 5-9% of pregnancies in Europe and in 
many other developed countries; while the rate in the USA is 12-13% 
[1]. The statistics indicate that preterm birth is the leading cause of 
neonatal morbidity and mortality; and appropriate tocolytic therapy 
is therefore one of the greatest challenges in obstetrical practice. A 
number of agents have been used clinically as tocolytics; but their 
efficacy is questioned. The approach to new therapeutic targets brings 
us to the investigation of endogenous mediators which play a role in 
the modulation of uterine contractility. 
After identification of the endogenous ligand nociceptin/
orphanin FQ (N/OFQ) for the orphan opioid receptor (NOP); another 
heptadecapeptide; nocistatin (NST); was isolated from the same 
precursor protein Prepronociceptin (PNOC) from bovine brains by 
Okuda-Ashitaka et al. [2] in 1998. NST was thought to be a functional 
antagonist of N/OFQ on the basis of their effects in the central nervous 
system [3-8]. Although N/OFQ has no affinity to opiate receptors; 
interaction was reported between the N/OFQ and dynorphin in 
neuropathic pain [9]. Other paper suggests that the classical opioid and 
the novel nociceptin system regulate nociception in parallel [10]. 
The epithelial cells of the human endometrium express the 
Corticotropin-Releasing Hormone (CRH) and opioid peptide 
precursors’ genes (i.e. proopiomelanocortin; proenkephalin; and 
prodynorphin) and their end-products. Additionally; given the 
myorelaxant actions of opioids; these endometrial neuropeptides may 
participate in the control of myometrial contractility [11]. Opioid 
agonists produce a concentration-dependent inhibition or excitation 
of spontaneous rhythmic or tonic contractions induced by potassium 
chloride (KCl) (50 mM) in the isolated rat uterus [12]. Thus; the opioid 
system plays a role in the regulation of uterine contractility.
As reported earlier by our group [13,14]; N/OFQ and NST; the 
translation products of the PNOC gene; inhibit uterine contractions 
in the pregnant rat. Despite a large body of literature on the role of 
opioid peptides in pain modulation in humans; limited information 
is available on their actions in the human uterus. The mechanisms of 
action of N/OFQ and NST remain largely unexplored [15]. 
In this work; we set out to detect the expression of PNOC mRNA 
in the human uterus; by means of an RT-PCR technique. We planned 
to study the in vitro effects of NST alone and also in combination with 
N/OFQ; and also to investigate the effects of N/OFQ alone and in 
combination with NST on the isolated human uterus. 
Materials and Methods
Human specimens
Biopsy specimens of human myometrial tissue were obtained 
at cesarean section (performed in the Department of Obstetrics and 
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Gynecology; University of Szeged) in the third trimester of pregnancy 
in two groups: at full-term birth (37-41 weeks of gestation; n=10) and 
at preterm birth (33-36 weeks; n=9). At full-term; cesarean delivery 
was indicated by a previous cesarean delivery; breech presentation; a 
suspected cephalopelvic disproportion or myopia. The parity varied 
from 0 to 3; and the mean maternal age was 28.4 years (21-35 years). 
None of the women received a tocolytic agent; and there were no signs 
of labor.
Preterm delivery occurred in mothers with twin pregnancies; or 
labor was indicated by an ongoing infection; leukocytosis; toxemia; fetal 
distress or growth restriction. In the preterm group; the parity varied 
from 0 to 3; and the mean maternal age was 28.2 years (18-38 years). 
Three of the 9 patients received tocolytic therapy (magnesium sulfate) 
to arrest preterm uterine contractions; which proved to be ineffective. 
All the operations were performed under spinal anesthesia. The Ethical 
Committee of Albert Szent-Györgyi Clinical Center; University of 
Szeged; approved the clinical protocol for the use of human tissue; 
the pregnant women signed an informed consent form; uninfluenced 
(registration number: 114/2009). 
RT-PCR (Real-time reverse transcription polymerase chain 
reaction) studies
The human uterus tissue samples were frozen in liquid nitrogen; 
and then stored at -80°C until analysis. The frozen samples were ground 
with a Micro-Dismembrator S homogenizer (Sartorius; Germany); 
and the total RNA was isolated with the TRIsure Kit according to the 
manufacturer’s instructions. RNA purity was controlled via the optical 
density at 260/280 nm with a BioSpec Nano instrument (Shimadzu; 
Japan); all samples exhibited an absorbance ratio in the range 1.6-2.0. 
RNA quality and integrity were assessed by agarose gel electrophoresis. 
One microgram of each sample of total RNA was used for reverse 
transcription and amplification (TaqMan RNA-to-CT 1-Step Kit and 
the Sensi FAST Probe Hi-Rox One-Step Kit). 
The following primers were used: assay ID Hs00173823_m1 for 
PNOC and Hs 01060665_g1 for ß-actin as endogenous control. RT-
PCR was performed by using the ABI StepOne Real-Time cycler. 
The fluorescence intensities of the probes were plotted against PCR 
cycle numbers. The amplification cycle displaying the first significant 
fluorescence signal increase was defined as the threshold cycle (CT).
In vitro contractility studies
Uterus preparation: Each tissue sample (10×10×30 mm) was 
obtained from the upper edge of a lower-segment transverse incision; 
after delivery of the child; but before oxytocin was given to the mother. 
Tissues were stored in Krebs–Henseleit solution (containing in mM: 
118 NaCl; 5 KCl; 2 CaCl2; 0.5 MgSO4; 25 NaHCO3; 1 KHPO4; 10 glucose; 
pH 7.4) at 4°C; until investigation; but within 12 hours of collection.
Longitudinal myometrial strips (~3×5×10 mm) were mounted 
vertically in an organ bath containing 10 ml Krebs–Henseleit solution. 
The organ bath was maintained at 37°C; and carbogen (95% O2+5% 
CO2) was bubbled through it. After mounting; the initial tension was 
set at 3.0 g and the rings were equilibrated for 90 min; with a solution 
change every 15 min.
In vitro studies in human uterus tissues from full-term births 
and from preterm births: In the isolated uterine rings; rhythmic 
contractions were elicited with 10-8 M oxytocin. The effects of N/
OFQ and NST on the uterine contractions were tested in the 
concentration range 10-12–10-6 M; in a non-cumulative manner. After 
each concentration of N/OFQ and NST; the rings were washed 3 times; 
allowed to recover for 5 min; and then contracted again with oxytocin. 
The uterus-relaxant effect of NST was also investigated in the presence 
of N/OFQ. Additionally; the uterus-relaxant effect of N/OFQ was 
investigated in the presence of NST. 
The tension of the myometrial rings was measured with a strain 
gauge transducer (SG-02; Experimetria Ltd; Budapest; Hungary); 
and recorded and analyzed with the SPEL Advanced ISOSYS Data 
Acquisition System (Experimetria Ltd; Budapest; Hungary). The areas 
under the curves of 6-min periods were evaluated; the effects of NST 
and N/OFQ were expressed as percentages of the oxytocin-induced 
contractions. The maximum relaxations were calculated with the 
Prism 4.0 computer program (GraphPad Inc.; San Diego; CA; USA). 
Statistical analyses were carried out with the ANOVA Newman-Keul 
test. 
Materials
N/OFQ and NST were purchased from PolyPeptide Laboratories 
France SAS; Strasbourg; France. Oxytocin was purchased from Richter 
Gedeon Ltd.; Budapest; Hungary. The TRIsure Kit and the Sensi FAST 
Probe Hi-Rox One-Step Kit were from Bioline Ltd.; Budapest; Hungary. 
TaqMan RNA-to-CT 1-Step Kit and ß-actin primer were obtained from 
Life Technologies; Budapest; Hungary.
Results
Measurement of PNOC mRNA in the human uterus
The myometrial PNOC mRNA levels were significantly higher in 
preterm uterine samples (RQ=35.40 ± 3.31) as compared with samples 
from full-term pregnancy (RQ=0.81 ± 0.12); p<0.001 (Figure 1).
In vitro contractility studies in the full-term pregnant human 
myometrium
N/OFQ alone decreased the uterine contractility concentration-
dependently. NST (10-8 M) increased the maximum uterus-relaxant 
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Figure 1: Levels of expression of Pnoc mRNA in human uterus samples 
obtained from preterm birth and full-term birth. By term pregnancy, the 
Pnoc mRNA level was decreased; there was a significant decline in the level 
of Pnoc in full-term uterine samples as compared with preterm samples; 
***p<0.001.
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effect of N/OFQ significantly (p<0.001; Figure 2A; Table 1). There was 
no significant difference between the EC50 values. NST alone exerted 
a uterus-relaxant effect. However; co-administration of N/OFQ (10-8 
M) with NST did not alter the uterus-relaxant effect of NST (p>0.05; 
Figure 2B). There was no significant difference between the EC50 values.
In vitro contractility studies in the pregnant human 
myometrium from preterm births
N/OFQ alone decreased the uterine contractility concentration-
dependently. NST (10-8 M) increased the maximum uterus-relaxant 
effect of N/OFQ significantly (p<0.001; Figure 2C). There was no 
significant difference between the EC50 values (data not shown). NST 
alone demonstrated a uterus-relaxant effect; which was not altered 
by N/OFQ (p>0.05; Figure 2D). There was no significant difference 
between the EC50 values.
Discussion
It is accepted that; whilst hormones such as oxytocin; vasopressin 
and prostaglandin F2alpha induce myometrial contractions; essentially 
via an elevation of the intracellular calcium level; other ligands; such 
as beta-adrenoceptor agonists and Calcitonin Gene-Related Peptide 
(CGRP); promote uterine quiescence via their ability to increase 
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Figure 2: Uterus-relaxant effects of nociceptin (N/OFQ) and nocistatin (NST) on the term- and preterm-pregnant human myometrium in vitro. The contractions were 
elicited with 10-8 M oxytocin in uterine rings from full-term (A, B) and preterm (C, D) human pregnancies. A) The concentration-dependent relaxing effect of N/OFQ 
(▲) was significantly increased in the presence of NST (10-8 M; ∆); n=6. B) The concentration-dependent relaxant effect of NST (●) was not altered by N/OFQ (10-8 
M; ○); n=4. C) The concentration-dependent relaxing effect of N/OFQ (▲) was significantly increased in the presence of NST (10-8 M; ∆); n=4. D) Co-administration 
of N/OFQ (10-8 M) with NST (○), however, did not significantly alter the uterus-relaxant effect of NST (●); n=5.
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intracellular cyclic AMP levels [16]. As NOP is expressed in a high 
proportion of substance P (SP)/CGRP-positive neurons; and as a 
major subpopulation of N/OFQ neurons is located in juxtaposition to 
SP/CGRP-positive neurons; it is proposed that N/OFQ released locally 
in the dorsal root ganglia may (in a paracrine manner) modulate SP/
CGRP-containing neurons expressing NOP. Thus; N/OFQ modulates 
both central and peripheral SP- or CGRP-mediated neurotransmission 
[17].
The CGRP system might play a role in the maintenance of normal 
pregnancy; and a defect in this system might lead to complications [18]. 
During pregnancy; circulating CGRP levels become significantly raised 
in humans [19,20] and rats [21]. The increase in CGRP levels begins in 
the third month of gestation in women; continuing until parturition; 
with the peak value (300% increase) in the ninth month [19].
We have previously demonstrated the CGRP-liberating effect of 
NST; and also the cAMP-accumulating and potassium channel opening 
effects of N/OFQ [13,14]. These mechanisms may additionally explain 
the uterus-relaxant effects of N/OFQ and NST and their intracellular 
signaling in the human uterus. As potassium channel inhibitors block 
CGRP-induced uterus relaxation; we assume that potassium channel 
opening is another signaling mechanism to relax the uterine smooth 
muscle by N/OFQ and NST. 
RT-PCR studies confirmed that PNOC; the precursor for both N/
OFQ and NST; shows an elevated level in preterm pregnancies; which 
is in correlation with the uterine quiescence during pregnancy. As a 
consequence; much more NST and N/OFQ can be translated from 
PNOC. The PNOC level drops by the end of pregnancy; when uterine 
contractility becomes stronger. 
The synergistic action of N/OFQ and NST is really surprising; 
because studies reported on their opposite effects in several biological 
functions [3-8,22,23]. However these studies were carried out in 
the Central Nervous System (CNS) and gave no information about 
the peripheral interaction of these two neuropeptides. Hence; the 
peripheral synergism of N/OFQ and NST is a novel finding and seems 
to be opposite as compared with their CNS effect.
We can also conclude that NST administration must precede the 
administration of N/OFQ with the aim of enhancing the common 
uterus-relaxant effect. We assume that the CGRP-liberating effect of 
NST results in a weaker relaxation as compared with the potassium 
channel opening effect of N/OFQ; repeated and increasing 
administrations of N/OFQ following NST can therefore further 
increase the uterus relaxation through the potassium channels. On the 
other hand; if N/OFQ is administered first; the CGRP liberating effect 
of NST cannot exceed the relaxation caused by a single dose of N/OFQ 
through potassium channel opening; therefore the relaxing effect of 
NST cannot be potentiated by N/OFQ significantly.
The more prominent potentiating effect of NST in N/OFQ-
stimulated uterus relaxation in preterm birth as compared with term 
pregnancy correlates with the finding that PNOC is more abundant in 
preterm birth.
As a conclusion; both N/OFQ and NST; possibly generated locally; 
have relaxant effects on the human uterus. Moreover; if they are 
present together; N/OFQ demonstrates an increased relaxant effect 
when NST is administered first. Further studies are required to reveal 
the precise mechanism of action of this potentiation. This potentiating 
effect is more prominent in the preterm myometrium; revealing the 
importance of the PNOC-N/OFQ-NST axis in the maintenance of 
quiescence in the pregnant human uterus.
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